Difficulty: Medium
Average Score: 76%
Practice
A 49-year-old man with long-standing schizophrenia is hospitalized for a symptom exacerbation. His primary care physician places him on a second-generation antipsychotic agent. Characteristics of this agent include which of the following?
Correct answer
B
Rationale
In this question, the correct answer is option B: "Have fewer extrapyramidal symptoms than first-generation agents." Second-generation antipsychotic agents, also known as atypical antipsychotics, are preferred over first-generation agents due to their reduced risk of causing extrapyramidal symptoms such as dystonia, akathisia, parkinsonism, and tardive dyskinesia. This is a crucial advantage as extrapyramidal symptoms can significantly impact a patient's quality of life and treatment adherence.
Option A, stating that second-generation antipsychotic agents are considered typical antipsychotic agents, is incorrect. Second-generation antipsychotics are classified as atypical antipsychotics due to their unique receptor binding profiles and reduced likelihood of causing extrapyramidal symptoms compared to typical antipsychotics.
Options C and D, indicating a low risk of developing diabetes mellitus and hypercholesterolemia, respectively, are incorrect. Second-generation antipsychotic agents are actually associated with metabolic side effects such as weight gain, insulin resistance, diabetes mellitus, and dyslipidemia. Educationally, understanding the differences in side effect profiles between first and second-generation antipsychotic agents is crucial for healthcare providers when making treatment decisions for patients with schizophrenia to optimize therapeutic outcomes while minimizing adverse effects.
Option A, stating that second-generation antipsychotic agents are considered typical antipsychotic agents, is incorrect. Second-generation antipsychotics are classified as atypical antipsychotics due to their unique receptor binding profiles and reduced likelihood of causing extrapyramidal symptoms compared to typical antipsychotics.
Options C and D, indicating a low risk of developing diabetes mellitus and hypercholesterolemia, respectively, are incorrect. Second-generation antipsychotic agents are actually associated with metabolic side effects such as weight gain, insulin resistance, diabetes mellitus, and dyslipidemia. Educationally, understanding the differences in side effect profiles between first and second-generation antipsychotic agents is crucial for healthcare providers when making treatment decisions for patients with schizophrenia to optimize therapeutic outcomes while minimizing adverse effects.